Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP789527.RA6RwYUOUoTpP0kF2ror_G9ECDWprtc2Y0NUkEaZ52hKY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP789527.RA6RwYUOUoTpP0kF2ror_G9ECDWprtc2Y0NUkEaZ52hKY130_assertion type Assertion NP789527.RA6RwYUOUoTpP0kF2ror_G9ECDWprtc2Y0NUkEaZ52hKY130_head.
- NP789527.RA6RwYUOUoTpP0kF2ror_G9ECDWprtc2Y0NUkEaZ52hKY130_assertion description "[E2A-PBX1+ adult ALL should be considered for intensified treatment strategies and monitoring of minimal residual disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP789527.RA6RwYUOUoTpP0kF2ror_G9ECDWprtc2Y0NUkEaZ52hKY130_provenance.
- NP789527.RA6RwYUOUoTpP0kF2ror_G9ECDWprtc2Y0NUkEaZ52hKY130_assertion evidence source_evidence_literature NP789527.RA6RwYUOUoTpP0kF2ror_G9ECDWprtc2Y0NUkEaZ52hKY130_provenance.
- NP789527.RA6RwYUOUoTpP0kF2ror_G9ECDWprtc2Y0NUkEaZ52hKY130_assertion SIO_000772 12580965 NP789527.RA6RwYUOUoTpP0kF2ror_G9ECDWprtc2Y0NUkEaZ52hKY130_provenance.
- NP789527.RA6RwYUOUoTpP0kF2ror_G9ECDWprtc2Y0NUkEaZ52hKY130_assertion wasDerivedFrom befree-20140225 NP789527.RA6RwYUOUoTpP0kF2ror_G9ECDWprtc2Y0NUkEaZ52hKY130_provenance.
- NP789527.RA6RwYUOUoTpP0kF2ror_G9ECDWprtc2Y0NUkEaZ52hKY130_assertion wasGeneratedBy ECO_0000203 NP789527.RA6RwYUOUoTpP0kF2ror_G9ECDWprtc2Y0NUkEaZ52hKY130_provenance.